{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:29:21Z","timestamp":1775896161096,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.esmoop.2024.103003","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T05:39:56Z","timestamp":1712986796000},"page":"103003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A new schedule of one week on\/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-4271","authenticated-orcid":false,"given":"C.","family":"von Arx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Della Vittoria Scarpati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Marretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bracigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Picozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1682-3792","authenticated-orcid":false,"given":"D.","family":"Iervolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-5803","authenticated-orcid":false,"given":"R.","family":"Modica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mocerino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pizzolorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Sarno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ottaiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2024.103003_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3892\/etm.2021.10613","article-title":"The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5","volume":"22","author":"Popa","year":"2021","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103003_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrendo.2011.120","article-title":"Neuroendocrine neoplasms of the gut and pancreas: new insights","volume":"8","author":"Rindi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103003_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"WHO Panel. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103003_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/B978-0-323-52357-8.00055-X","article-title":"Neuroendocrine tumors of the lung other than small cell lung cancer","author":"Noonan","year":"2018","journal-title":"IASLC Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103003_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103003_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11864-021-00866-9","article-title":"Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma","volume":"22","author":"Mollazadegan","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103003_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103003_bib8","first-page":"1224","article-title":"Safety and activity of metronomic temozolomide in second- line treatment of advanced neuroendocrine neoplasms","volume":"8","author":"Tafuto","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103003_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy use, performance status, and quality of life at the end of life","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103003_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00001813-200308000-00003","article-title":"Inhibition of angiogenesis by non-toxic doses of temozolomide","volume":"14","author":"Kurzen","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103003_bib11","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103003_bib12","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/ERC-11-0287","article-title":"Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours","volume":"19","author":"Koumarianou","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103003_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11060-013-1048-z","article-title":"\u201cOne week on-one week off\u201d: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center","volume":"112","author":"Galldiks","year":"2013","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103003_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11060-012-0832-5","article-title":"Dose dense 1 week on\/1 week off temozolomide in recurrent glioma: a retrospective study","volume":"108","author":"Taal","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103003_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103003_bib17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/74969","article-title":"Chemotherapeutic drugs--more really is not better","volume":"6","author":"Fidler","year":"2000","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103003_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3727\/096504021X16214197880808","article-title":"Evaluation of MGMT gene methylation in neuroendocrine neoplasms","volume":"28","author":"Della Monica","year":"2022","journal-title":"Oncol Res"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103003_bib19","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103003_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12967-016-0857-1","article-title":"Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma","volume":"14","author":"De Divitiis","year":"2016","journal-title":"J\u00a0Transl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103003_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1215\/15228517-2008-078","article-title":"New (alternative) temozolomide regimens for the treatment of glioma","volume":"11","author":"Wick","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2024.103003_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13046-015-0274-y","article-title":"Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in\u00a0vivo and in\u00a0vitro","volume":"35","author":"Sun","year":"2016","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103003_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ctrv.2017.02.007","article-title":"IEO ENETS Center of Excellence for GEP NET. Metronomic and metronomic-like therapies in neuroendocrine tumors - rationale and clinical perspectives","volume":"55","author":"Lambrescu","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103003_bib24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3340\/jkns.2015.58.5.426","article-title":"Continuous low-dose temozolomide chemotherapy and microvessel density in recurrent glioblastoma","volume":"58","author":"Woo","year":"2015","journal-title":"J\u00a0Korean Neurosurg Soc"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103003_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103003_bib26","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/170496","article-title":"Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas","volume":"2012","author":"Olsen","year":"2012","journal-title":"ScientificWorldJ"},{"issue":"20","key":"10.1016\/j.esmoop.2024.103003_bib27","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103003_bib28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103003_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103003_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.esmoop.2024.103003_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102015","article-title":"NET-02: a randomised, noncomparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"60","author":"McNamara","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:49Z","timestamp":1762598689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924007713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2059702924007713"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103003","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new schedule of one week on\/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103003"}}